PT - JOURNAL ARTICLE AU - Sandeep Budhiraja AU - Mona Aggarwal AU - Monica Mahajan AU - Abhaya Indrayan AU - Vinita Jha AU - Ambrish Mittal AU - Sanjay Sachdeva AU - Sumit Mrig AU - Anurag Jain AU - Ravinder Gera AU - Rahul Aggarwal AU - Suven Kalra AU - WVPS Ramalingam AU - Anupal Deka AU - Arjun Das AU - D Jijina AU - Ajit Mansingh AU - Anuj Singhal AU - Rajashekhar Reddi AU - Puneet Aggarwal AU - Mukesh Kumar AU - JD Mukherjee AU - Vivek Nangia AU - Ajay Lall AU - Omender Singh AU - Arun Dewan AU - Ajay Jain AU - Gita G Shrivastava AU - Mala Bhattacharjee AU - Meena Nihalani AU - Manoj Kumar AU - Meenakshi Jain AU - Mukesh Mehra AU - Vijay Arora AU - Viresh Prashant Mehta AU - Dilip Bhalla AU - Amit Batra AU - Rajesh Gupta AU - Vivek Kumar AU - Sanjeev Dua AU - Praveen Pandey AU - Y P Singh AU - Mohit Mathur AU - Ashok Singh AU - Sanjeev Arora AU - Ajay Kumar Gupta AU - Pankaj Nand Choudhary AU - Manoj Singh AU - Namita Kaul AU - Sitla Prasad Pathak AU - Sharad Joshi AU - Manish Gupta AU - Rajesh Mishra AU - Alok Joshi AU - Manoj Aggarwal AU - Rajiv Gupta AU - Vandana Boobna AU - Yogesh Kumar Chhabra AU - Inder Mohan Chugh AU - Sandeep Garg AU - Vikas Mittal AU - Neha Sood AU - Anil Kumar AU - Rajesh Kumar Pande AU - V P Singh AU - Iram Khan AU - Nitin Garg AU - Puneet Tyagi AU - Shantanu Belwal AU - Anup Kumar Roy AU - Deepak Bhasin AU - Sachin Pandove AU - Ravikant Bahl AU - Prateek Soni TI - Profile of Mucormycosis Cases from a Network of Hospitals in North India Amidst COVID-19 Pandemic AID - 10.1101/2021.08.25.21262404 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.25.21262404 4099 - http://medrxiv.org/content/early/2021/08/28/2021.08.25.21262404.short 4100 - http://medrxiv.org/content/early/2021/08/28/2021.08.25.21262404.full AB - Incidence of mucormycosis suddenly surged in India after the second wave of COVID-19. This is a crippling disease and needs to be studied in detail to understand the disease, its course, and the outcomes.Between 1st March and 15th July 2021, our network of hospitals in North India received a total of 155 cases of COVID-associated mucormycosis cases as all of them reported affliction by COVID-19 earlier or concurrent. Their records were retrieved from the Electronic Health Records system of the hospitals and their demographics, clinical features, treatments, and outcomes were studied. More than 80% (125 cases) had proven disease and the remaining 30 were categorized as ‘possible’ mucormycosis as per the EORTC criteria.More than two-thirds (69.0%) of the cases were males and the mean age was 53 years for either sex. Nearly two-thirds (64.5%) had symptoms of nose and jaws and 42.6% had eye involvement. Some had multiple symptoms. As many as 78.7% had diabetes and 91.6% gave history of use of steroids during COVID-19 treatment. The primary surgery was functional endoscopic sinus surgery (FESS) (83.9%). Overall mortality was 16.8%, which is one-and-a-half times the mortality in hospitalized COVID-19 patients in the corresponding population. Occurrence of mucormycosis was associated with diabetes and use of steroids, but mortality was not associated with either of them. Cases undergoing surgery and on antifungal had steeply lower mortality (11.9% vs. 50.0%, P < 0.001) than those who were exclusively on antifungal drugs. Treatment by different drugs did not make much of a difference in mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any financial contribution from any funding agency/source.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Ethics Committee, Max Super Speciality Hospital (A unit of Devki Devi Foundation), Address : Service Floor, Office of Ethics Committee, East Block, next to Conference Room, Max Super Speciality Hospital, Saket (A unit of Devki Devi Foundation), 2, Press Enclave Road, Saket, New Delhi 110017 vide ref. no. BHR/RS/MSSH/DDF/SKT-2/IEC/IM/21-19 dated 19th July2021. The IEC provided no objection and approved the publication of this manuscript. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is a retrospective, observational, multi-centre study that included all the cases recorded as mucormycosis either at discharge or at death, between 1st March 2021 and 15th July 2021 in our network of hospitals in North India. Their records were retrieved from the Electronic Health Records system and their demographic and clinical profile, the hospital course, and the outcome were noted.